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Background: More information is needed on the anatomopathological outcome variables indicating the
appropriate surgical strategy for the colorectal resections often needed during cytoreduction for ovarian cancer.
Methods: From a phase-II study cohort including 70 patients with primary advanced or recurrent ovarian cancer
with diffuse peritoneal metastases treated from November 2000 to April 2009, we selected for this study the 52
consecutive patients who needed colorectal resection. Data collected included type of colorectal resection,
peritoneal cancer index (PCI), histopathology (depth of bowel-wall invasion and lymph-node spread), cytoreduction
rate and outcome. Correlations were tested between possible prognostic factors and Kaplan-Meier five-year overall
and disease-free survival. A Cox multivariate regression model was used to identify independent variables
associated with outcome.
Results: In the 52 patients, the optimal cytoreduction rate was 86.5% (CC0/1). In all patients, implants infiltrated
deeply into the bowel wall, in 75% of the cases up to the muscular and mucosal layer. Lymph-node metastases
were detected in 50% of the cases; mesenteric nodes were involved in 42.3%. Most patients (52%) had an
uneventful postoperative course. Operative mortality was 3.8%. The five-year survival rate was 49.9% and five-year
disease-free survival was 36.7%. Cox regression analysis identified as the main prognostic factors completeness of
cytoreduction and depth of bowel wall invasion.
Conclusions: Our findings suggest that the major independent prognostic factors in patients with advanced
ovarian cancer needing colorectal resections are completeness of cytoreduction and depth of bowel wall invasion.
Surgical management and pathological assessment should be aware of and deal with dual locoregional and
mesenteric lymphatic spread.
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Epithelial ovarian cancer is the fifth most frequent cause
of cancer death in women and remains the leading cause
of gynecologic cancer-related deaths in the US and
Europe [1,2]. Although aggressive surgical cytoreduction
and platinum- plus taxane-based chemotherapy have in
recent years improved median overall survival in ad-
vanced ovarian cancer [3,4], relapse rates reach 80% and
long-term cure rates languish between 20 and 30% [4-6].
After a meta-analysis demonstrated the prognostic value
of maximal cytoreduction [7], the definition of desir-
able surgical outcome switched from so-called ‘optimal
debulking’ with variable residual disease up to 1 to 2 cm
[8], to microscopic residual disease alone [9-12], justify-
ing more aggressive surgery. To improve the outcome in
treating patients with primary advanced or recurrent ovar-
ian cancer, given the known benefits of normothermic in-
traperitoneal chemotherapy [13], some have combined
cytoreduction (peritonectomy procedures) with hyper-
thermic intraperitoneal chemotherapy (HIPEC) [14-16].
As Hoffman et al. report, in about 26% of these pa-
tients the various visceral resections needed to reach
maximal cytoreduction include colorectal resections
[17]. Besides wide consensus on the need for colorectal
resections to reduce residual disease, many investigators
also emphasize the acceptable complications rate and
the fact that, in most cases, the colorectum can be
resected, avoiding an intestinal stoma [18,19]. Some
compared the long-term results in patients who needed
a colorectal resection (for example a rectosigmoid resec-
tion) and those in whom it could be avoided simply by
removing the peritoneum in the Douglas pouch. Hardly
surprisingly, they found that the results in the two
groups overlapped [20] because outcomes in patients
with advanced ovarian cancer depend crucially on the
completeness of cytoreduction achieved, regardless of
the surgical procedures used. No studies have yet clearly
identified prognostic factors linking colorectal resection
required during cytoreduction in these patients with
survival.
Seeking a better guide to surgical management, we
designed this study to assess anatomopathological out-
come variables correlated with large-bowel involvement
in patients with primary advanced or recurrent ovarian
cancer with diffuse peritoneal metastases. To do so,
from a larger consecutive series of prospectively enrolled
patients with advanced ovarian cancer treated in our
center with peritonectomy procedures and HIPEC, we
selected for study those patients in whom cytoreduction
required colorectal resections. Univariate and multivari-
ate regression analyses were used to determine the prog-
nostic value of several outcome variables including
completeness of cytoreduction, depth of bowel wall inva-
sion and lymph node spread.Methods
From a phase II trial including a cohort of 70 patients
with primary advanced or recurrent ovarian cancer with
diffuse peritoneal metastases treated with peritonectomy
and HIPEC from November 2000 to April 2009, we se-
lected for study the 52 consecutive patients who had
ovarian implants invading at least a single colorectal seg-
ment confirmed by intraoperative assessment and re-
quiring colorectal resection. Colorectal resection was
required because macroscopic disease in the colorectal
segment, pouch or mesentery or both made it impossible
to clear in situ malignant implants or attempt serosal
stripping of the visceral surface. The inclusion criteria
for peritonectomy were age younger than 75 years; his-
tologically or cytologically confirmed diagnosis; perform-
ance status 0 to 2 (WHO); adequate cardiac, renal,
hepatic and bone marrow function; resectable disease;
and informed written consent. The exclusion criteria
were extra-abdominal metastases; other malignancies ex-
cept breast cancer; unresectable disease; active infection
or severe associated medical conditions. The extent of
malignant peritoneal disease was assessed with the peri-
toneal cancer index (PCI) - a scoring system ranging from
0 to 39 according to the extent of metastasis into the peri-
toneal cavity [21]. The completeness of cytoreduction
(CC) was scored as CC0: no residual disease; CC1: re-
sidual nodules measuring less than 2.5 mm; CC2: residual
nodes measuring between 2.5 mm and 2.5 cm; and CC3
residual nodules greater than 2.5 cm [22]. Aggressive sur-
gical cytoreduction followed the standard accepted tech-
niques for peritonectomy [23].
When the tumor mass involved the pelvis, cul-de-sac,
uterus and adnexa and rectosigmoid colon, or recurrent
bulky disease involved the pelvis, maximal cytoreductive
surgery usually comprised an en bloc resection including
the internal female genitalia or pelvic recurrence along
with the rectum and sigmoid, according to the pelvic
peritonectomy technique [23]. Our policy envisaged a low
distal rectal section just above the pelvic diaphragm, com-
prising the mesorectum, leaving a rectal stump no longer
than 5 cm. The inferior mesenteric artery was tied at its
origin from the aorta and the vein at the ligament of
Treitz. Patients with peritoneal implants involving the
cecum, appendix, terminal ileum or ascending colon
underwent a standard right hemicolectomy. In patients
with diffuse colonic involvement, every effort was made to
preserve as much colon as possible by clearing malignant
implants from the surface [24]. Patients with peritoneal
spread involving the pelvis and all colonic segments, with
nodules penetrating deeply into the colonic wall, under-
went total colectomy and rectal resection.
When each surgical procedure ended, HIPEC was given
under general anesthesia with the closed technique and
during hemodynamic monitoring. Cisplatin at a dose of
Table 1 Patients’ demographic and clinical characteristics
(52 patients)
Characteristics N (%)
Age (years) mean 62 (range 32–76)
Primary cytoreduction 30 (57.7%)


















Ca125 level mean 579.25 U/ml (range 15
to 6800 U/ml)
Peritoneal cancer index (PCI) mean 18.8 (range 6 to 28)
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43°C was given for 60 minutes. The technique used for
HIPEC has been detailed in our preceding work [14].
The patients were admitted to the intensive care unit
(ICU) for at least the first 24 hours after operation. Cis-
platin toxicity, surgical complications and adverse events
were graded from 0 to V according to the National Can-
cer Institutes Common Toxicity Criteria [25,26].
All patients were followed up by members of the sur-
gical staff and referred to the medical oncologic staff to
plan systemic chemotherapy. Outpatient clinic visits for
follow-up assessment were scheduled according to the
individual patient’s conditions.
Anatomopathological features studied in detail for
each patient included the depth of malignant bowel wall
invasion (serosal, muscle and mucosal layers) and lymph
node spread. Lymph nodes were identified, taking into
account dual polarity (locoregional and mesenteric)
lymph node spread, and classified by site, distinguishing
between locoregional ovarian (pelvic, obturator and
interaortocaval stations) and mesenteric (pericolic, and
mesorectal) nodes.
A multiple regression analysis was used to test correla-
tions between possible prognostic factors. Survival was
expressed as median months, and as five-year overall
and disease-free rates. The Kaplan-Meier method was
used to construct survival curves and the log-rank test
(univariate analysis) was used to assess the significance
of differences between curves. The Cox multivariate re-
gression model was used to determine the prognostic
value of independent variables. P values <0.05 were con-
sidered to indicate statistical significance. The NCSS
package (NCSS, LLC, Kaysville, UT, USA) was used to
analyze the database and conduct statistical tests.
All patients gave their informed consent to the study.
The procedures were approved by the institutional re-
view board at Policlinico Umberto I Rome and the re-
search complied with the Helsinki Declaration.
Results
Patients’ demographic and clinical characteristics are
reported in Table 1.
In the 52 patients selected for study because malignant
disease required colorectal resections, peritonectomy
procedures during cytoreduction comprised a mean
number of 7.5 resections per patient (Table 2). During
primary cytoreductive surgery, ovarian locoregional
lymph nodes were routinely dissected whereas during
secondary cytoreductive surgery, they were dissected in
only 10 of the 22 patients who underwent cytoreduction
because the procedure had not been done at the first op-
eration. All the 52 patients selected because they under-
went colorectal resection had site-specific mesenteric
lymphadenectomy (Table 2).Complete cytoreduction (CC-0) was achieved in 28
(53.8%) of the patients, CC-1 in 17 (32.7%), CC-2 in 5
(9.6%) and CC-3 in 2 (3.8%), yielding an 86.5% rate of
optimal cytoreduction (CC-0 and CC-1).
Peritonectomy procedures lasted a mean 510 minutes
(range 300 to 780) including 60 minutes HIPEC. All op-
erations led to major blood loss (mean 1700 ml, range
500 to 4900) and required intraoperative blood (mean 4,
range 2 to 8 units) and plasma (mean 6, range 2 to 10
units) transfusions.
Most patients (52%) had an uneventful postoperative
course. The only HIPEC-related adverse events were
renal cisplatin toxicity (2 cases, grade 1 in one and grade
2 in the other patient), and medical treatment reversed
both drug-induced reactions.
Grade I/II complications developed in 23.1%, grade III
in 7.7% and grade IV in 13.4% of the patients. Of the
seven patients with grade IV complications, six under-
went a second operation, two for colonic fistulas both
unrelated to colorectal anastomoses but caused by the
surgical maneuvers needed to ablate colonic implants,
two for postoperative bleeding, one patient for a small
bowel fistula due to a perforation that developed during
Table 2 Types of resection during peritonectomy
(52 patients)
Type of colorectal resection N (%)
Rectal resection + left hemicolectomy 24 (46.1%)
Rectal resection + total colectomy 18 (34.6%)
Rectal resection + right hemicolectomy and
left hemicolectomy
6 (11.5%)
Right hemicolectomy 4 (7.7%)
Total 52 (100%)
Associated visceral resections N (%)
Hysterectomy ± adnexectomy 35 (67.3%)
Pelvic mass resection 6 (11.5%)
Omental resection 49 (94.2%)
Liver resection 2 (3.8%)
Cholecystectomy 14 (26.9%)
Splenectomy 28 (53.8%)
Small bowel resection 16 (30.8%)
Appendectomy 11 (21.1%)
Total cystectomy 1 (1.9%)
Bladder resection 3 (5.8%)
Total peritonectomy 10 (19.3%)
Partial peritonectomy 42 (80.7%)
Abdominal wall resection 13 (25%)
Resection or reduction of cancer implants 51 (92.7%)
Locoregional + mesenteric lymphadenectomy 40 (76.9%)
Mesenteric lymphadenectomy alone 12 (23.1%)




Total surgical procedures 389 (mean 7.5)
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patient returned to the ICU on postoperative day 6 after
a myocardial infarction. Two patients died of pulmonary
embolism despite anticoagulant treatment (operative
mortality 3.8%). Mean postoperative stay was 21.6 days
(range 8 to 90). After hospital discharge all but two pa-
tients were fit for postoperative systemic chemotherapy.
Histopathology typed most tumors (71.5%) as serous
carcinomas followed by mucinous carcinoma (17.3%), and
endometrioid cancer (11.5%). In all 52 cases malignant im-
plants infiltrated the colorectal wall: in 13 (25%) the ser-
osa; in 35 (67.3%) the muscular; and in 4 (7.7%) reaching
the mucosal layer. Multiple regression analysis showed
that the depth of bowel wall involvement significantly cor-
relates with more extensive peritoneal spread (PCI >18)
and with overall lymph node metastases (Table 3).
Seeking dual polarity nodal spread, in the 52 patients
we examined a mean of 24.3 (range 7 to 49) locoregionalovarian lymph nodes and a mean of 27.3 (range 14 to
60) mesenteric and mesorectal nodes per patient. Lymph
node metastases were detected in 50% of the patients
and involved the mesenteric nodes more frequently than
the ovarian locoregional nodes (30.8% vs. 7.7%), and in
11.5% of the cases involved both stations (Table 3). Of
the 48 patients who underwent a rectal resection, 20
(41.6%) had mesorectal lymph node metastases. Of the
prognostic variables assessed (depth of colorectal wall
invasion, number of colorectal resections, presence of
locoregional node metastases and extent of peritoneal
involvement), the only predictive factor that correlated
significantly with mesenteric node metastases was the
number of colorectal resections (P <0.01) (Table 3).
At a mean follow-up of 73.5 months (range 36 to 118),
the overall five-year Kaplan-Meier survival rate in the 52
patients was 49.9% and the disease-free survival rate was
36.7%. The overall median survival was 28 months and
the median disease-free survival was 20 months. For the
patients optimally debulked (CC-0 and CC-1) survival
reached a value of 35.5 months overall and 32.5 months
disease-free.
Univariate analysis (log-rank test) identified as the
prognostic factors significantly correlated with long-term
(five-year) survival, the CC score (P <0.002) and degree
of colorectal-wall involvement (P <0.037). Cox regres-
sion model verifying the relationship between survival
and combined prognostic factors confirmed that the
only independent variables significantly influencing pa-
tients’ survival were CC score (P <0.003) and depth of
colorectal-wall involvement (P <0.004) (Table 4).
Discussion
For this study, from a larger series of patients who
underwent cytoreductive surgery plus HIPEC for pri-
mary advanced or recurrent ovarian cancer with diffuse
peritoneal metastases, we explicitly selected those in
whom cytoreduction included colorectal resections. This
selection criterion allowed us to confirm and extend
current knowledge on anatomopathological factors cor-
related with large bowel involvement that could influ-
ence outcome and survival. In our series, surgical
cytoreduction called frequently for colorectal resections
(52 in the original series of 70 patients, 74.3%) because,
as a tertiary referral center for the integrated treatment
of peritoneal carcinomatosis, the patients we treat typic-
ally have a high index of peritoneal spread (mean PCI
18.8, range 6 to 28).
When we compared our results with those of others
who analyzed the surgical specimens removed in detail
[20,27-35] - investigating the depth of invasion into the
large bowel wall, mesenteric lymph node spread, their
relation to survival, and overall survival in patients who
underwent optimal cytoreduction - several distinctive
Table 3 Anatomopathological outcome variables (52 patients)
Depth of colorectal wall involvement (52 patients) N (%)
Serosal layer 13 (25%)
Muscular layer 35 (67.3%)
Mucosal layer 4 (7.7%)
Multiple regression report
Dependent variable Independent variable T value Prob level
Depth of colorectal wall involvement n colorectal resections >1 −0.274 n.s.
total colectomy 0.341 n.s.
PCI >18 3.709 0.0005
Lymph node metastases 2.990 0.004
Lymph node site and status (52 patients) N (%)
N0 26 (50%)
N+ locoregional lymph nodes (A) 4 (7.7%)
N+ mesenteric lymph nodes (B) 16 (30.8%)
A + B 6 (11.5%)
Mesenteric lymph node status and possible predictive factors (52 patients) Mesenteric nodes
node positive node negative
n° patients n° patients
Depth of colorectal wall involvement (P = ns)
Serosal layer 6 7
Muscular and mucosal layers 16 23
Number of colorectal resections (P <0.01)
Single resection 7 21
Double resection 5 1
Total colectomy 10 8
Locoregional lymph node status (P = ns)
Positive 6 4
Negative 16 26
Peritoneal cancer index (P = ns)
PCI < 18 7 15
PCI ≥ 18 15 15
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that the Cox regression analysis identified the depth of
colorectal wall invasion as an independent prognostic
factor statistically equal to the amount of residual dis-
ease (Table 4). None of the patients in whom large bowel
wall invasion reached the mucosa survived more than
three years. The considerable prognostic importance that
the depth of invasion into the large bowel wall attained
in our series partly agrees with the only two similar pre-
vious reports that underlined this finding [29,31]. In the
series conducted by Scarabelli et al. the depth of large
bowel wall invasion achieved prognostic value in the
multivariate analysis only in patients with co-existing
mesenteric lymph node metastases [29]. Conversely, inthe patients studied by Park et al. this variable attained
significant prognostic value in the log-rank test only
for the disease-free interval whereas the significance
disappeared when they analyzed overall survival [31].
We attribute the strong prognostic value for the depth
of large bowel wall invasion to the lower percentage of
patients with serosal invasion alone in our series than in
others (serosal layers 25% vs. a mean of 44.5%) and to
the higher mean percentage of patients with malignant
disease infiltrating deep into the large bowel wall (mus-
cular and mucosal layers 75% vs. mean 55.4%) (P <0.01)
(Table 5). The worse outcome in patients with deeper
large bowel wall involvement can be explained by the
multiple regression analysis showing that the depth of
Table 4 Prognostic factors and five-year survival by univariate and multivariate analysis (52 patients)
Prognostic factors Variables Five-year survival P* (univariate analysis) P** (multivariate analysis)
Patients’ age (years) <62 52.2% 0.49 0.79
≥62 41.2%
Ascites Absent 39.2% 0.97 0.08
Present 47.5%
Obstruction Absent 56.7% 0.64 0.59
Present 25.4%
Cytoreduction Primary 47.2% 0.98 0.73
Secondary 37.4%
Peritoneal cancer index <18 53.5% 0.08 0.17
≥18 33.6%
Completeness of cytoreduction score CC-0 55% 0.002 0.003
CC 1-3 25.7%
Depth of colorectal wall involvement Serosal layer 72.7% 0.037 0.004
Muscular layer 33.1%
Mucosa layer 0%
Lymph node status N0 41.3% 0.67 0.76
N+ (A) 75%
N+ (B) 42.5%
N+ (A + B) 27.7%
P* by log-rank test; P** by Cox regression model. A, locoregional lymph nodes; B, mesenteric lymph nodes.
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extensive peritoneal spread (PCI >18) and with overall
lymph-node metastases (Table 3).
The second finding in our series, in which cytoreductive
surgery with colorectal resection invariably included mes-
enteric lymphadenectomy, was the 42.3% frequency of
metastatic spread to the mesenteric lymph nodes. This
frequency accords with the figure reported by Dvorethsky
et al. reported in an autopsy study on 100 patients [36].
In the studies we analyzed (Table 5), the wide variability
in metastatic mesenteric node spread - from 15.2%
reported by Park et al. [31] to 93.5% reported by Salani
et al. [33] - presumably depends on the lack of a system-
atic surgical protocol for mesenteric lymphadenectomy in
these patients [33]. Some investigators underline that the
frequency of mesenteric lymph node spread correlates sig-
nificantly with certain pathologic variables [28,31,33]. For
example, Park et al. related malignant mesenteric lymph
node spread to the depth of colorectal wall invasion [31],
Salani et al. to retroperitoneal lymph-node spread [33]
and Lax et al. to the amount of colorectum resected [28].
In their later study Baiocchi et al. found a significant cor-
relation between mesenteric lymph node spread and the
depth of colorectal wall invasion and the presence of me-
tastases at the retroperitoneal lymph node stations [34].
Our experience underlines that whenever metastatic peri-
toneal spread in advanced ovarian cancer invades the
colorectal wall, one can reasonably expect mesentericlymph node involvement equal to or even greater than
that in the typical pelvic and interaortocaval locoregional
lymph node stations (Table 3). The incidence of these me-
tastases correlates significantly with number of colorectal
segments involved and the extent of colorectal resections
undertaken (Table 3), as Lax et al. have underlined [28].
When we analyzed the site of the involved mesenteric
lymph node stations, in 41.6% of the patients in whom
cytoreduction required a rectal resection we found evi-
dent metastatic spread to the mesorectal lymph nodes,
alone or in association with other sites. Our finding and
the 39.4% recently reported by Gouy et al. [35], fully jus-
tify our decision to base our surgical strategy on the gen-
eral criteria for surgical oncology. In patients in whom
malignant disease infiltrated deep into the peritoneal
pouch and intraperitoneal rectum, we used an approach
analogous to that generally used for rectal cancer, namely
an almost total mesorectal excision. In our series, neither
the univariate nor the multivariate analysis identified
overall lymph node status as a significant prognostic indi-
cator. Although concurrent locoregional ovarian and mes-
enteric lymph node involvement worsened patients’
outcomes the difference failed to reach statistical signifi-
cance. This finding agrees with O’Hanlan et al. and Lax
et al. who reported that mesenteric lymph-node involve-
ment worsened the outlook though not significantly
[27,28]. Others more recently, Gallotta et al. [20], and
Gouy et al. [35], reported similar survival in patients with
Table 5 Colorectal involvement in advanced ovarian cancer: literature review
Author/year Patients
(number)
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Present series 52 Serosa 25 42.3 Prognostic significance of depth




Mucosa 7.7 32.5 months disease-free
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observation that mesenteric lymph-node metastases espe-
cially if associated with locoregional lymph-node metasta-
ses worsen the prognosis, though not significantly,
underlines the need for systematic lymphadenectomy, aprocedure that is valuable for disease staging and is also
therapeutically useful. If unrecognized lymph node disease
were left in situ, patients with and without mesenteric
lymph node spread would presumably no longer have a
similar outcome.
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in our series of patients with diffuse peritoneal spread
from ovarian cancer in whom cytoreductive surgery in-
cluded colorectal resection, our data rank high among
the literature, especially given emerging evidence show-
ing that diffuse ovarian peritoneal spread worsens out-
comes [37].
Conclusions
In patients with primary advanced or recurrent ovarian
cancer with diffuse peritoneal metastases and colorectal
involvement, the depth of colorectal wall invasion seems
to be an independent prognostic factor equal to residual
disease. Even though consensus now regards colorectal
resections when needed as an accepted procedure during
cytoreduction, the depth of colorectal wall invasion in
these patients could be especially useful as a new criter-
ion for stratifying patients into prognostic classes, a need
that others have underlined [6]. When the diagnostic
work-up discloses malignant disease invading the colo-
rectal wall up to the mucosal layer, neoadjuvant chemo-
therapy could help to down-stage the disease.
A major concern that surgeons and pathologists
should be aware of and deal with in patients with pri-
mary advanced or recurrent ovarian cancer involving the
large bowel is dual locoregional and mesenteric lymph-
atic spread. Our experience corroborates previous evi-
dence that the surgical technique for colorectal resection
in these patients should strictly follow the criteria used
for colorectal cancer [27,29].
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